Evening Brief: Shanghai Flu Activity Surges; Musk's Neuralink Demonstrates Mind-Controlled Robotic Arm with 'Steel Kiss,' Theoretically Capable of Controlling Anything

(Source:Bio Valley）

Source: Bioon

1. Influenza Activity Intensity Rises in Shanghai

Flu Activity Intensifies in Shanghai, with Increased Clustered Cases in Schools and Childcare FacilitiesSince December 1, multiple specialized children’s hospitals have reported a gradual rise in outpatient visits among kindergarten, primary, and secondary school students. Visits to fever clinics, emergency departments, respiratory medicine departments, and general pediatrics departments have increased compared to the previous month. On December 2, the positivity rate for Influenza A nucleic acid tests at the Shanghai Children’s Hospital reached approximately 60%, marking a significant increase since December 1. On December 3, the influenza detection rate at the Shanghai Children’s Medical Center was around 40%, with a 20% week-on-week increase in patient volume at fever clinics and emergency departments over the past week.

2. Musk’s Brain-Computer Interface Enables Mind-Controlled Robotic Arm; Demonstrator Receives a “Steel Kiss,” Theoretically Capable of Controlling Anything

New Developments in Elon Musk’s Brain-Computer Interface Neuralink: Demonstrator Achieves Mind-Controlled Robotic Arm in Official Video; Musk States That Neuralink Can Theoretically Indirectly Control Everything. Meanwhile, Neuralink is advancing upgrade trials using a “dual-implant” approach, with the first participant potentially undergoing a second surgery to establish a “digital neural bridge” aimed at helping paralyzed patients regain the ability to walk. The technical team has completed key iterations addressing issues with the first-generation product, improving surgical procedures to ensure long-term signal stability. Current R&D efforts are shifting toward bidirectional signal bridging between the brain and spinal cord. In the future, this technology will not only serve medical restoration purposes but also aim to increase information transmission bandwidth, enabling participants’ reaction speeds and digital interaction efficiency to surpass those of average individuals. Additionally, participants are actively exploring new applications of the brain-computer interface; for instance, the third participant has mounted a webcam on their wheelchair to address visual field limitations caused by amyotrophic lateral sclerosis (ALS).

3. The lipid-lowering drug market is fiercely competitive, with more than 20 pharmaceutical companies focusing on this blockbuster drug

The rising global incidence of cardiovascular disease is driving steady growth in the lipid-lowering drug market, which reached a size of USD 33.12 billion in 2023 and is projected to increase to USD 46.58 billion in ten years. In China, sales of lipid-lowering drugs have exceeded RMB 25 billion. Recently, domestic pharmaceutical companies have accelerated their R&D efforts; Jiangsu Ouge Pharmaceutical’s marketing application for Rosuvastatin and Ezetimibe Tablets (I) has been accepted. The originator of this drug is Sanofi, which received approval for launch in China at the end of 2023 and was included in the National Reimbursement Drug List in 2024, making it the first approved single-pill combination formulation of rosuvastatin and ezetimibe in China. By 2025, there had already beenFuyuan PharmaceuticalGeneric versions from three pharmaceutical companies have been approved for market launch. Moreover, over 20 companies, including Zhejiang Nuode Pharmaceutical and Shijiazhuang No.4 Pharmaceutical, have submitted applications for the marketing approval of generic versions of this drug this year, which are currently under regulatory review. Pharmaceutical companies are focusing on this drug primarily due to its significant lipid-lowering efficacy, excellent safety profile, and broad market prospects.

4. Peking University Hospital Adds New Beijing Key Laboratory, Illuminating Precision Medicine for Severe Kidney Diseases

On November 30, the “Beijing Key Laboratory for Precision Diagnosis and Treatment of Critical Kidney Diseases: Research and Development of Pharmaceuticals and Medical Devices” was unveiled and officially launched at Peking University First Hospital, marking a crucial step forward in the construction of an innovation platform in this field. The event was attended by numerous experts. Academician Zhan Qimin of the Chinese Academy of Engineering delivered the keynote address, emphasizing the need to orient efforts toward public health needs and build a modern medical innovation system. He stated that the new laboratory should integrate into the development of Beijing as a national science and technology innovation center, contributing its “Peking University”Great Wisdom”. Relying on the Department of Nephrology at Peking University First Hospital, the laboratory was jointly established with multiple institutions to explore translational models and build a demonstration base and collaborative network. The Academic Committee meeting was chaired by Zhan Qimin, and Professor Yang Li, Director of the Key Laboratory, presented a report. The laboratory is seizing opportunities in the new era of nephrology by proposing three strategic goals: “Precision Nephrology,” “Smart Nephrology,” and “Digital Nephrology.” These initiatives are respectively dedicated to developing new methods, technologies, and devices; constructing a closed-loop system for full-lifecycle management; and advancing renal imaging omics and digital twin kidneys.

5. A Key Biotech Project in Lanzhou Rapidly Takes Root, Adding a New Engine to the Northwest Stem Cell Industry

According to a report by Lanzhou Evening News, the first phase of the key investment attraction project in Qilihe District for 2025—Ainuoyin Stem Cell Biotechnology (Gansu) Co., Ltd.—has been officially delivered and put into operation. Based in Lanzhou and radiating across the Gansu-Qinghai-Ningxia region, the project has established a comprehensive cellular laboratory complex in Northwest China that integrates stem cell storage with regenerative medicine applications. This initiative fills a regional industry gap and injects new momentum into the upgrading of the healthcare sector in Western China. The corporate exhibition hall, characterized by its strong technological ambiance, serves as a window for public education on cell science and the display of scientific research progress. As the western strategic pillar of Qingchen Group’s big health industry, the project centers on “R&D of cellular application technologies” to build an integrated chain. Its rapid implementation benefits from the superior business environment in Qilihe District. The first phase has completed multiple construction tasks, focusing on the clinical translation of stem cells and immune cells. The second laboratory is scheduled to be completed in the first half of 2026, with the goal of achieving a full-chain closed loop within two years.